- Rheumatoid Arthritis
- Osteoarthritis
- Psoriatic Arthritis
- Gout
- Fibromyalgia
- Lupus
- Lyme Disease
- Osteoporosis
- Sjögren’s Syndrome
Ocrelizumab, a Humanized Anti-CD20 Monoclonal Antibody, Studied for the Treatment of RA
Ocrelizumab, a fully human monoclonal antibody against CD20, may have less immunogenicity and less complement activation than rituximab which, theoretically, may reduce the development of drug neutralizing antibodies and infusion reactions.
PAD-4 Autoantibodies Identified as a Novel Severity Factor in RA
Antibodies against citrullinated proteins have emerged as powerful diagnostic and prognostic tools in RA that may contribute to the initiation phases of the disease.
Arthritis News
- FDA Arthritis Advisory Board Recommends the Approval of Tocilizumab (Actemra) for the Treatment of RA- August 25th, 2008
- CDC Releases New Guidelines for Use of Zoster Vaccine in Immunosuppressed Patients - August 12th, 2008
- Immune Tolerance Induced by Chicken Type II Collagen as Treatment for RA - July 24th, 2008
- Increasing the Dose of Etanercept not Efficacious in Rheumatoid Arthritis - July 16th, 2008
- FDA Launches Safety Review of TNF Inhibitors in Children - June 25th, 2008
- New Onset Psoriatic Arthritis Reported in Psoriasis Patients Treated with Efalizumab
- Denosumab, an inhibitor of RANKL, suppresses erosions but has no effect on articular signs and symptoms in rheumatoid arthritis
Support for this site is provided through unrestricted educational grants from
Amgen, Abbott Immunology, Bristol-Myers Squibb, Centocor , and Genentech
- Physician News
- Addressing Challenges in RA : The Role of B- and T-Cell Targeted Therapies
- Rheumatoid Arthritis Update: Current & New Therapeutics
Highlights from the American College of Rheumatology Conference 2007
Pathophysiology of the Rheumatic Diseases - 2007- Video - Topics in Clinical Rheumatology - Arthritis Foundation - Maryland Chapter
- Video - 2007 Summer Rheumatology Conference